Clinical trials: Glucagon
Glucose Metabolism, Glucagon
Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants
In this study the investigators will investigate the acute effects of increasing glucagon exposure on metabolic parameters in healthy participants. Participants will participate in one study day.
- Trial name
- NCT06921824
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Healthy
Studies of the Early Meal Phase in Healthy Individuals - Nutrient Absorption and Gastrointestinal Hormone Secretion
To investigate gastrointestinal hormone secretions and nutrient absorption during the early meal phase we will recruit 12 healthy young men. They will be equipped with peripheral intravenous catheters for frequent blood sampling.
- Trial name
- NCT03543423
- Testing
- Oral glucose tolerance test, Liquid mixed meal test
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Cardiovascular Diseases
Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers
The study seeks to explore the cardiovascular effects of co-agonism at two peptide receptors, GLP-1 and glucagon. Glucagon, exenatide and 0.9% saline will be intravenously infused, both in isolation, and combination into healthy…
- Trial name
- COCOA (NCT03835013)
- Testing
- Saline 0.9%, Glucagon (25ng/kg/min), Glucagon (50ng/kg/min)
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Bariatric Surgery (Gastric Bypass), Overweight
The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation
The purpose of this study is to determine the type of macronutrient (carbohydrate, lipid or protein) that most potently stimulates the endogen secretion of different gut hormones (primary outcome = Glucagon-Like peptide-1) in…
- Trial name
- NCT02372526
- Testing
- Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes, Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes, Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes
- Where
- Denmark
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kirstine Nyvold Bojsen-Moeller
Healthy
Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones
Glucagon has been used for decades as a test of growth hormone (GH) reserve. The pathway by which GH is stimulated by glucagon is not established.
- Trial name
- NCT01795235
- Testing
- Saline, Glucagon, Atenolol
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Type 2 Diabetes Mellitus
Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion
We want to investigate how lack of glucagon suppression during an oral glucose tolerance test in patients with type 2 diabetes contributes to patients postprandial hyperglycemia.
- Trial name
- EGP_Glucagon (NCT02010827)
- Testing
- isoglycemic intravenous glucose infusion and Glucagon infusion, day C, Oral glucose tolerance test, day A, intravenous iv glucose infusion, day B
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Non-Insulin-Dependent
NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes
The purpose of this research study is to investigate the mechanism of action of a new investigational medication (drug), NNC 90-1170, which is being developed for the treatment of type 2 diabetes (adult onset type of diabetes.
- Trial name
- NCT00013910
- Testing
- NNC 90-1170
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Non-Alcoholic Fatty Liver Disease, Glucagon Resistance
The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover
Many patients with type 2 diabetes exhibit elevated plasma concentrations of the glucose-mobilising pancreatic hormone glucagon; i.e. hyperglucagonaemia.
- Trial name
- NCT04859322
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Malte Palm Suppli, MD
End-stage Renal Disease
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
Patients with end-stage renal disease (ESRD) have a high prevalence of impaired glucose metabolism. The pathophysiological cause is uncertain, but disturbances in the secretion, elimination and effect of glucagon, insulin and the…
- Trial name
- NCT02237521
- Testing
- Eu- and hyperglycemic clamp, Arginine test
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bo Feldt-Rasmussen
Type 2 Diabetes Mellitus
A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)
This is a study to assess the pharmacokinetics, safety, and tolerability of sequential single oral doses of MK-8093 10 mg, 40 mg, 200 mg, or placebo to MK-8093 (Part 1) depending on treatment assignment in young healthy male…
- Trial name
- NCT02012166
- Testing
- MK-0893 10 mg, MK-0893 40 mg, MK-0893 200 mg
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Neoplasms, Stomach Neoplasms
Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
Improvements to treatment strategies for patients upper gastrointestinal cancers have produced an increasing population of people who remain free from disease recurrence in the long term.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition
- Trial name
- NCT02385617
- Testing
- Octreotide
- Where
- 2 sites in Ireland, Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- St. James's Hospital, Ireland
Gastric Retention
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
Glucagon-like peptide-1 agonists (GLP-1RA) are a family of medications used for diabetes and weight loss. One of their effect is to slow down stomach emptying.
- Trial name
- RESIDUAL (NCT06500143)
- Testing
- Gastric ultrasound
- Where
- Canada
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Laxity; Skin
Assess Impact of Poly-L-lactic Acid on GLP1 Subjects
Clinical trial to evaluate treatments of double-dilute poly-L-lactic acid on abdominal skin laxity in GLP1 patients versus non GLP1 patients.
- Trial name
- NCT07217743
- Testing
- Sculptra Aesthetic
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
Kidney Diseases
The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.
This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels.
- Trial name
- NCT06872060
- Testing
- Glucagon, Glucagon+Exendin9-39, Sodium chloride
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Glucose Metabolism Disorders
The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion
Delineation of the anatomical location, cellular origin and molecular basis of gut-derived glucagon secretion
- Trial name
- NCT03181191
- Testing
- Oral glucose tolerance test
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Bariatric Surgery
Incretin Hormone Antagonism After Bariatric Surgery
Using the glucagon-like peptide-1 (GLP-1) antagonist exendin(9-39) and the glucose-dependent insulinotropic peptide (GIP) antagonist GIP(3-30), the purpose of this study is to clarify the importance of endogenous GLP-1 and GIP…
- Trial name
- INCA-BAR (NCT03950245)
- Testing
- GLP-1 antagonism, GIP antagonism, GLP-1 and GIP antagonism
- Where
- 2 sites in Denmark
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Hypoglycemia
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.
- Trial name
- NCT00745186
- Testing
- Glucagen, Mayne Glucagon
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study.
- Trial name
- NCT05202353
- Testing
- BI 456906, Semaglutide
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Adult Participants
Effects of an Arabinoxylan-enriched Rusk on Postprandial Glucose, Insulin, Glucagon-like Peptide-1 and Appetite Responses
The aim of the present pilot randomized controlled trial is to compare the effects of the following: 1)-rusk enriched with arabinoxylans (r-rich), 2)-rusk not enriched (r-standard) on blood glucose, insulin values, glucagon like…
- Trial name
- NCT07682857
- Testing
- Enriched rusk, Standard rusk
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Turin, Italy
Healthy Adult Subject, Overweight Subject
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects.
- Trial name
- NCT06601517
- Testing
- Repaglinide, Atorvastatin, Digoxin
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.